DUSA up on actinic keratosis data

DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) gained $0.37 to $5.75 on Thursday after Levulan Kerastick followed by DUSA's

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE